-=Allergan Plc (AGN) reported earnings on Tue 30 Oct 2018 (b/o)

Oct 30 (Reuters) - Allergan Plc reported a 3 percent drop in quarterly revenue on Tuesday, as its faces increasing competition for its Alzheimer's treatment Namenda and other branded drugs.

The company posted net loss attributable to ordinary shareholders of $37.9 million, or 11 cents per share, in the third quarter ended Sept. 30, compared with loss of $4.03 billion, or $12.07 per share, a year ago, which included a one-time charge.

Revenue fell 3 percent to $3.91 billion.

Allergan beats by $0.21, reports revs in-line; raises FY18 EPS, revs guidance 

• Reports Q3 (Sep) earnings of $4.25 per share, excluding non-recurring items, $0.21 better than the S&P Capital IQ Consensus of $4.04; revenues fell 3.0% year/year to $3.91 bln vs the $3.89 bln S&P Capital IQ Consensus.
• Co raises guidance for FY18, sees EPS of $16.20-16.60 (Prior $16.00-16.50), excluding non-recurring items, vs. $16.38 S&P Capital IQ Consensus; sees FY18 revs of $15.55-15.7 bln (Prior $15.45-15.6 bln) vs. $15.63 bln S&P Capital IQ Consensus.